GlassScriptPhysician profile
Benjamin L Dozeman
NPI 1134332794
$4,100.03
in general payments reported to CMS, 2019-2025
21 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $410 · 2021: $75.75 · 2022: $370 · 2023: $767 · 2024: $772 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Education: $34.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.81 |
| Education | $34.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.24 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Takeda Pharmaceuticals U.S.A., INC. | $773.46 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $392.19 | 2019-2024 | Xifaxan |
| Pfizer INC. | $371.48 | 2019-2025 | |
| Celgene Corporation | $290.66 | 2022-2024 | Zeposia |
| Shionogi INC | $203.87 | 2019-2020 | |
| Janssen Biotech, INC. | $177.93 | 2019-2025 | Stelara, Remicade, Simponi |
| Ucb, INC. | $152.73 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $130.40 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $122.95 | 2022-2024 | Dupixent |
| Genzyme Corporation | $93.77 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $64.37 | 2019-2020 | |
| Gilead Sciences, INC. | $55.16 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.24 | 2021 | |
| Ardelyx, INC. | $46.46 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.46 | 2025 | Wegovy |
| Lilly USA, LLC | $24.74 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $23.90 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $22.52 | 2025 | Varithena Administration Pack |
| Glaxosmithkline, LLC. | $21.14 | 2025 | Bexsero |
| Braintree Laboratories, INC. | $19.36 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dozeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.